Urgent.News

What's breaking now, across hundreds of outlets.

Health & Medicine

Glaukos' Epioxa Shows Durable Three-Year Results In Keratoconus

(RTTNews) - Glaukos Corp. (GKOS) on Wednesday reported three-year results from a Phase 3 extension study evaluating Epioxa, its epithelium-on corneal cross-linking therapy for keratoconus.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Source: nasdaq.com

Read the original at nasdaq.com →

Report a problem with this story

More in Health & Medicine

More from Thursday 8 October →